The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ORIC Pharmaceuticals Inc. | COM | 68622P109 | 35,938,887 | 3,540,777 | SH | SOLE | 3,540,777 | 0 | 0 | ||
| RAPT Therapeutics Inc | COM | 75382E109 | 10,628,904 | 1,328,613 | SH | SOLE | 1,328,613 | 0 | 0 | ||
| Revolution Medicines Inc | COM | 76155X100 | 1,692 | 46 | SH | SOLE | 46 | 0 | 0 | ||
| Surrozen, Inc. | COM | 86889P109 | 13,407,971 | 1,499,773 | SH | SOLE | 1,499,773 | 0 | 0 | ||
| Tenaya Therapeutics, Inc. | COM | 87990A106 | 5,743,577 | 9,400,290 | SH | SOLE | 9,400,290 | 0 | 0 | ||